About EpiBone
EpiBone is a company based in Brooklyn (United States) founded in 2013 by Elisa Cimetta, Sarindr Bhumiratana, and Sidney Eisig. EpiBone has raised $48.63 million across 10 funding rounds from investors including HHS, Hackensack Meridian Health and EMV Capital. EpiBone offers products and services including Bioreactor and Personalized Bone Products. EpiBone operates in a competitive market with competitors including ViaCyte, Capricor Therapeutics, Neurona Therapeutics, MiMedx Group and Ossio, among others.
- Headquarter Brooklyn, United States
- Founders Elisa Cimetta, Sarindr Bhumiratana, Sidney Eisig
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$48.63 M (USD)
in 10 rounds
-
Latest Funding Round
$4.29 M (USD), Series B
Sep 02, 2025
-
Investors
HHS
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EpiBone
EpiBone offers a comprehensive portfolio of products and services, including Bioreactor and Personalized Bone Products.
Device that grows personalized bone from stem cells for healing.
Custom-grown bone and cartilage to replace damaged tissue.
People of EpiBone
Unlock access to complete
Unlock access to complete
Funding Insights of EpiBone
EpiBone has successfully raised a total of $48.63M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $4.29 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EpiBone
EpiBone has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Hackensack Meridian Health and EMV Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are focused on health technology breakthroughs.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
B2B-tech focused VC firm
|
Locked | Locked | Locked |
Investor details for EpiBone
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EpiBone
Investment portfolio details for EpiBone
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EpiBone
Detailed financials for EpiBone
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Epibone Comparisons
Peer comparison for EpiBone
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EpiBone
EpiBone operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ViaCyte, Capricor Therapeutics, Neurona Therapeutics, MiMedx Group and Ossio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell therapy for diabetes is developed from stem cells.
|
|
| Locked | Locked | Locked |
Regenerative medicine for cardiovascular disorders is developed using cell-based platforms.
|
|
| Locked | Locked | Locked |
Cell-based therapies are developed for intractable neurological diseases.
|
|
| Locked | Locked | Locked |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics
|
|
| Locked | Locked | Locked |
Orthopedic fixation is enabled by bone regeneration biocomposite technology.
|
Detailed competitors of EpiBone
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Epibone
Complete news archive for EpiBone
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EpiBone
EpiBone was founded in 2013 and raised its 1st funding round 1 year after it was founded.
EpiBone is headquartered in Brooklyn, United States. It is registered at Brooklyn, New York, United States.
EpiBone is a funded company, having raised a total of $48.63M across 10 funding rounds to date.
Founded in 2013 and based in Brooklyn, United States, the company operates in the biotechnology sector focused on regenerative medicine. Custom autologous bone grafts are engineered through a bioreactor platform, where CT scan data is used to create anatomically shaped scaffolds. These scaffolds are seeded with stem cells from the patients own tissue and matured in a proprietary bioreactor system for bone preconditioning and development.
EpiBone's top competitors include Theradaptive, MiMedx Group and Neurona Therapeutics.
EpiBone offers Bioreactor and Personalized Bone Products.
EpiBone has 8 investors. Key investors include HHS, Hackensack Meridian Health, EMV Capital, Plum Alley Investments, and EMV Capital.